BERLIN – November 27, 2020. Morrison & Foerster LLP (MoFo) advised Medios AG (Medios), a specialty pharmaceutical company listed on the SDAX, on taking over the Hamburg specialty pharmaceutical wholesaler Cranach from the holding company BMSH GmbH. The transaction value amounts to over 120 million euro. Approval from the Federal Cartel Office is still pending. Cranach focuses on pharmaceuticals in the fields of neurology, hematology, and endocrinology, as well as ophthalmology, rheumatology, and oncology. The acquisition of Cranach is intended to enable Medios to better position itself as a full-service provider in the specialty pharmaceutical sector.
The MoFo team worked with managing partner Dr. Dirk Besse on the transaction, which was structured as a contribution in kind against the issue of over four million new Medios shares. MoFo has been advising Medios AG on an ongoing basis on capital market and corporate law matters ever since supporting its successful reverse IPO in 2017.
Morrison & Foerster’s team: Dr. Dirk Besse, managing partner (Corporate/M&A); Dr. Sebastian Schwalme, counsel (Corporate/M&A); Paula Paprocki, associate (Corporate/M&A); Julian Gebauer, associate (Corporate/M&A); Dr. Andreas Grünwald, partner (Antitrust); Dr. Wolfgang Schönig, partner (IP/Pharma); Robert Grohmann, Associate (IP/Pharma); (Dr. Jens-Uwe Hinder, partner (Tax); Dr. Angela Kerek, partner (Finance)
Seller’s legal advisor: FGvW Friedrich Graf von Westfalen & Partner Rechtsanwälte mbB: Dr. Stefan Lammel, Dr. Morton Douglas, Dr. Stephanie von Riegen, and Constantin Cadmus
Notary: Ralph Negelein (Heuking Kühn)
More information on the transaction can be found at the following links: